Evidence map›Paper›PMID 41029220›Full record

Observational studyBMC pregnancy and childbirth2025

The added value of the sFlt-1/PlGF ratio in pregnant women with intrauterine growth restriction (IUGR) with or without preeclampsia on adverse pregnancy outcomes and neonatal morbidities: a retrospective study.

Lieselot Arnouts, Janne Terwingen, Karlijn Van Damme, Dominique Mannaerts

Abstract readObservational Study
In one paragraph

Observational study in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lieselot ArnoutsDepartment of Gynecology and Obstetrics, University Hospital Antwerp, Drie Eikenstraat 655, Edegem, 2650, Belgium. lieselot_arnouts@hotmail.com.
Janne TerwingenDepartment of Gynecology and Obstetrics, University Hospital Antwerp, Drie Eikenstraat 655, Edegem, 2650, Belgium.
Karlijn Van DammeDepartment of Neonatology, University Hospital of Antwerp, Drie Eikenstraat 655, Edegem, 2650, Belgium.
Dominique MannaertsDepartment of Gynecology and Obstetrics, University Hospital Antwerp, Drie Eikenstraat 655, Edegem, 2650, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe sFlt-1/PlGF (soluble fms-like tyrosine kinase-1/placental growth factor) ratio in serum of pregnant women is a predictive marker for preeclampsia (PE). PE is often associated with intrauterine growth restriction (IUGR). Overall, growth-restricted fetuses are at increased risk for neonatal morbidities and perinatal death. An increased sFlt-1/PlGF ratio may be valuable for discriminating between different causes of IUGR. The goal of this study is to investigate the added value of the sFlt-1/PlGF ratio in pregnant women with IUGR on adverse pregnancy outcomes, neonatal morbidities and mortality.

methodsThis was a retrospective, monocenter, observational study conducted at the University Hospital of Antwerp. All singleton pregnancies with IUGR and known serum levels of sFlt-1/PlGF with a gestational age of 24 weeks until 37 weeks were included. The results were analyzed over a period of almost three years (January 2022 until October 2024). In total, 85 patients met the inclusion criteria, ten of whom had not raised serum levels of sFlt-1/PlGF (values less than 85), whereas the other 75 patients had increased sFlt-1/PlGF ratios. The maternal characteristics, fetal and neonatal mortality rates, adverse pregnancy outcomes and neonatal morbidities of all the patients and their neonates were recorded and analyzed.

resultsIn IUGR fetuses with increased maternal serum sFlt-1/PlGF ratios, aberrant ultrasonic fetal doppler, fetal demise and obstetrical diseases such as PE are more often observed. In the group of neonates from mothers with a raised sFlt-1/PlGF ratio, more neonatal morbidities, such as respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, early-onset sepsis, late-onset sepsis and retinopathy of prematurity, are observed. Nevertheless, it is important to correct those results for GA and birth weight since morbidities are more often observed in more premature neonates.

conclusionIn patients with IUGR due to placental insufficiency, an increased sFlt-1/PlGF ratio is observed. Only in the group with an increased sFlt-1/PlGF ratio did intrauterine fetal death occur. During pregnancy, more obstetrical diseases and a greater need for medication were observed. Neonatal outcomes always need to be corrected for GA and birth weight, but therefore, the inclusion number was too low.

Indexed as

Fetal Growth RetardationPlacenta Growth FactorPre-EclampsiaVascular Endothelial Growth Factor Receptor-1AdultBiomarkersFemaleGestational AgeHumansInfant, NewbornPregnancyPregnancy OutcomeRetrospective StudiesBiomarkersFLT1 protein, humanPGF protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Fetal mortalityIUGRMaternal morbiditiesNeonatal morbiditiesNeonatal mortalitySFlt-1/PlGF ratio

Identifiers

PMID41029220
PMCPMC12486873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.